BridgeBio Pharma to Present ATTRibute-CM Data at European Society of Cardiology Congress 2025.

BridgeBio Pharma will present data from its ATTRibute-CM study at the European Society of Cardiology Congress 2025. The presentations will focus on the effects of acoramidis on cardiovascular mortality and NT-proBNP levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The data will be shared through a rapid-fire oral presentation and two ePosters.

BridgeBio Pharma (Nasdaq: BBIO) is set to present additional open-label extension data from its ATTRibute-CM study at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentations will focus on the effects of acoramidis, a transthyretin stabilizer, on cardiovascular mortality and NT-proBNP levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) [1].

The company will deliver a rapid-fire oral presentation titled "Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study" on Saturday, August 30 at 1:15 pm CEST/7:15 am ET. The presentation will be led by Kevin Alexander, M.D. from Stanford University School of Medicine, USA [1].

Additionally, two ePosters will be presented. The first, titled "Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study," will be presented by Nitasha Sarswat, M.D. of UChicago Medicine, USA on Sunday, August 31 at 4:15 pm CEST/10:15 am ET. The second, titled "Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM Study," will be presented by Julian Gillmore, M.D., Ph.D., University College London's Centre for Amyloidosis, UK on Saturday, August 29 at 3:15 pm CEST/9:15 am ET [1].

Attruby™ (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. The study results will provide insights into the efficacy and safety of acoramidis in managing ATTR-CM, a condition that significantly impacts patients' cardiovascular health [1].

The presentations will be significant for investors and financial professionals as they will offer real-world evidence of the drug's effectiveness and potential market impact. BridgeBio Pharma's commitment to advancing genetic medicine and its pipeline of development programs make it a company to watch in the biopharmaceutical sector [2].

References:
[1] https://www.stocktitan.net/news/BBIO/bridge-bio-to-present-additional-open-label-extension-data-from-att-oobhx6xm66jp.html
[2] https://finance.yahoo.com/news/bridgebio-present-additional-open-label-113000853.html